Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Clinical and Translational Oncology
Published in: Clinical and Translational Oncology 3/2024

14-08-2023 | Ovarian Cancer | REVIEW ARTICLE

CircRNA-regulated glucose metabolism in ovarian cancer: an emerging landscape for therapeutic intervention

Authors: Yaolong Wang, Xi Chen, Yongxiu Yang

Published in: Clinical and Translational Oncology | Issue 3/2024

Login to get access

Abstract

Ovarian cancer (OC) has the highest mortality rate among female reproductive system tumours, with limited efficacy of traditional treatments and 5-year survival rates that rarely exceed 40%. Circular RNA (circRNA) is a stable endogenous circular RNA that typically regulates protein expression by binding to downstream miRNA. It has been demonstrated that circRNAs play an important role in the proliferation, migration, and glucose metabolism (such as the Warburg effect) of OC and can regulate the expression of glucose metabolism-related proteins such as GLUT1 and HK2, promoting anaerobic glycolysis of cancer cells, increasing glucose uptake and ATP production, and affecting energy supply and biosynthetic substances to support tumour growth and invasion. This review summarises the formation and characteristics of circRNAs and focuses on their role in regulating glucose metabolism in OC cells and their potential therapeutic value, providing insights for identifying new therapeutic targets.
Literature
1.
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.PubMedCrossRef
2.
Wang Z, Guo E, Yang B, Xiao R, Lu F, You L, et al. Trends and age-period-cohort effects on mortality of the three major gynecologic cancers in China from 1990 to 2019: cervical, ovarian and uterine cancer. Gynecol Oncol. 2021;163(2):358–63.PubMedCrossRef
3.
Armstrong DK, Alvarez RD, Backes FJ, Bakkum-Gamez JN, Barroilhet L, Behbakht K, et al. NCCN guidelines® insights: Ovarian cancer version 3.2022. J Natl Compr Canc Netw. 2022;20(9):972–80.PubMedCrossRef
4.
5.
O’Malley DM. New therapies for ovarian cancer. J Natl Compr Canc Netw. 2019;17(5.5):619–21.PubMed
6.
Emmings E, Mullany S, Chang Z, Landen CN Jr, Linder S, Bazzaro M. Targeting mitochondria for treatment of chemoresistant ovarian cancer. Int J Mol Sci. 2019;20(1):229.PubMedPubMedCentralCrossRef
7.
Koppenol WH, Bounds PL, Dang CV. Otto Warburg’s contributions to current concepts of cancer metabolism. Nat Rev Cancer. 2011;11(5):325–37.PubMedCrossRef
8.
Fukushi A, Kim HD, Chang YC, Kim CH. Revisited metabolic control and reprogramming cancers by means of the warburg effect in tumor cells. Int J Mol Sci. 2022;23(17):10037.PubMedPubMedCentralCrossRef
9.
10.
Vaupel P, Schmidberger H, Mayer A. The Warburg effect: essential part of metabolic reprogramming and central contributor to cancer progression. Int J Radiat Biol. 2019;95(7):912–9.PubMedCrossRef
11.
Icard P, Shulman S, Farhat D, Steyaert JM, Alifano M, Lincet H. How the Warburg effect supports aggressiveness and drug resistance of cancer cells? Drug Resist Updat. 2018;38:1–11.PubMedCrossRef
12.
Apostolova P, Pearce EL. Lactic acid and lactate: revisiting the physiological roles in the tumor microenvironment. Trends Immunol. 2022;43(12):969–77.PubMedCrossRef
13.
14.
15.
Martínez-Reyes I, Chandel NS. Cancer metabolism: looking forward. Nat Rev Cancer. 2021;21(10):669–80.PubMedCrossRef
16.
Abdel-Wahab AF, Mahmoud W, Al-Harizy RM. Targeting glucose metabolism to suppress cancer progression: prospective of anti-glycolytic cancer therapy. Pharmacol Res. 2019;150: 104511.PubMedCrossRef
17.
Tondo-Steele K, McLean K. The “Sweet Spot” of targeting tumor metabolism in ovarian cancers. Cancers (Basel). 2022;14(19):4696.PubMedCrossRef
18.
Tekade RK, Sun X. The Warburg effect and glucose-derived cancer theranostics. Drug Discov Today. 2017;22(11):1637–53.PubMedCrossRef
19.
20.
21.
22.
Nava GM, Madrigal Perez LA. Metabolic profile of the Warburg effect as a tool for molecular prognosis and diagnosis of cancer. Expert Rev Mol Diagn. 2022;22(4):439–47.PubMedCrossRef
23.
Meng S, Zhou H, Feng Z, Xu Z, Tang Y, Li P, et al. CircRNA: functions and properties of a novel potential biomarker for cancer. Mol Cancer. 2017;16(1):94.PubMedPubMedCentralCrossRef
24.
Li Z, Zhang H. Reprogramming of glucose, fatty acid and amino acid metabolism for cancer progression. Cell Mol Life Sci. 2016;73(2):377–92.PubMedCrossRef
25.
Greene J, Segaran A, Lord S. Targeting OXPHOS and the electron transport chain in cancer; molecular and therapeutic implications. Semin Cancer Biol. 2022;86(Pt 2):851–9.PubMedCrossRef
26.
Morita M, Sato T, Nomura M, Sakamoto Y, Inoue Y, Tanaka R, et al. PKM1 Confers metabolic advantages and promotes cell-autonomous tumor cell growth. Cancer Cell. 2018;33(3):355-367.e7.PubMedCrossRef
27.
Israelsen WJ, Vander Heiden MG. Pyruvate kinase: function, regulation and role in cancer. Semin Cell Dev Biol. 2015;43(43):51.
28.
İlhan M. Non-metabolic functions of pyruvate kinase M2: PKM2 in tumorigenesis and therapy resistance. Neoplasma. 2022;69(4):747–54.PubMedCrossRef
29.
Eniafe J, Jiang S. The functional roles of TCA cycle metabolites in cancer. Oncogene. 2021;40(19):3351–63.PubMedCrossRef
30.
Dier U, Shin DH, Hemachandra LP, Uusitalo LM, Hempel N. Bioenergetic analysis of ovarian cancer cell lines: profiling of histological subtypes and identification of a mitochondria-defective cell line. PLoS ONE. 2014;9(5): e98479.ADSPubMedPubMedCentralCrossRef
31.
Li N, Zhan X, Zhan X. The lncRNA SNHG3 regulates energy metabolism of ovarian cancer by an analysis of mitochondrial proteomes. Gynecol Oncol. 2018;150(2):343–54.MathSciNetPubMedCrossRef
32.
Anderson AS, Roberts PC, Frisard MI, McMillan RP, Brown TJ, Lawless MH, et al. Metabolic changes during ovarian cancer progression as targets for sphingosine treatment. Exp Cell Res. 2013;319(10):1431–42.PubMedPubMedCentralCrossRef
33.
Xintaropoulou C, Ward C, Wise A, Queckborner S, Turnbull A, Michie CO, et al. Expression of glycolytic enzymes in ovarian cancers and evaluation of the glycolytic pathway as a strategy for ovarian cancer treatment. BMC Cancer. 2018;18(1):636.PubMedPubMedCentralCrossRef
34.
Ma Y, Wang W, Idowu MO, Oh U, Wang XY, Temkin SM, et al. Ovarian cancer relies on glucose transporter 1 to fuel glycolysis and growth: anti-tumor activity of BAY-876. Cancers (Basel). 2018;11(1):33.PubMedCrossRef
35.
Baczewska M, Supruniuk E, Bojczuk K, Guzik P, Milewska P, Konończuk K, et al. Energy Substrate transporters in high-grade ovarian cancer: gene expression and clinical implications. Int J Mol Sci. 2022;23(16):8968.PubMedPubMedCentralCrossRef
36.
Ciscato F, Ferrone L, Masgras I, Laquatra C, Rasola A. Hexokinase 2 in cancer: A prima donna playing multiple characters. Int J Mol Sci. 2021;22(9):4716.PubMedPubMedCentralCrossRef
37.
Tian X, Liu D, Zuo X, Sun X, Wu M, Li X, et al. Hexokinase 2 promoted cell motility and proliferation by activating Akt1/p-Akt1 in human ovarian cancer cells. J Ovarian Res. 2022;15(1):92.PubMedPubMedCentralCrossRef
38.
Suh DH, Kim MA, Kim H, Kim MK, Kim HS, Chung HH, et al. Association of overexpression of hexokinase II with chemoresistance in epithelial ovarian cancer. Clin Exp Med. 2014;14(3):345–53.PubMedCrossRef
39.
Garcia SN, Guedes RC, Marques MM. Unlocking the potential of HK2 in cancer metabolism and therapeutics. Curr Med Chem. 2019;26(41):7285–322.PubMedCrossRef
40.
Feng J, Li J, Wu L, Yu Q, Ji J, Wu J, et al. Emerging roles and the regulation of aerobic glycolysis in hepatocellular carcinoma. J Exp Clin Cancer Res. 2020;39(1):126.PubMedPubMedCentralCrossRef
41.
Lincet H, Kafara P, Giffard F, Abeilard-Lemoisson E, Duval M, Louis MH, et al. Inhibition of Mcl-1 expression by citrate enhances the effect of Bcl-xL inhibitors on human ovarian carcinoma cells. J Ovarian Res. 2013;6(1):72.PubMedPubMedCentralCrossRef
42.
Kruspig B, Nilchian A, Orrenius S, Zhivotovsky B, Gogvadze V. Citrate kills tumor cells through activation of apical caspases. Cell Mol Life Sci. 2012;69(24):4229–37.PubMedCrossRef
43.
Wang X, Yin Y, Qian W, Peng C, Shen S, Wang T, et al. Citric acid of ovarian cancer metabolite induces pyroptosis via the caspase-4/TXNIP-NLRP3-GSDMD pathway in ovarian cancer. Faseb j. 2022;36(6): e22362.PubMedCrossRef
44.
Kopinski PK, Singh LN, Zhang S, Lott MT, Wallace DC. Mitochondrial DNA variation and cancer. Nat Rev Cancer. 2021;21(7):431–45.PubMedCrossRef
45.
Ju HQ, Lin JF, Tian T, Xie D, Xu RH. NADPH homeostasis in cancer: functions, mechanisms and therapeutic implications. Signal Transduct Target Ther. 2020;5(1):231.PubMedPubMedCentralCrossRef
46.
47.
Pramono AA, Rather GM, Herman H, Lestari K, Bertino JR. NAD- and NADPH-contributing enzymes as therapeutic targets in cancer: an overview. Biomolecules. 2020;10(3):358.PubMedPubMedCentralCrossRef
48.
San-Millán I, Brooks GA. Reexamining cancer metabolism: lactate production for carcinogenesis could be the purpose and explanation of the Warburg effect. Carcinogenesis. 2017;38(2):119–33.PubMed
49.
Zhang Y, Zhai Z, Duan J, Wang X, Zhong J, Wu L, et al. Lactate: the mediator of metabolism and immunosuppression. Front Endocrinol (Lausanne). 2022;13: 901495.PubMedCrossRef
50.
Stern R, Shuster S, Neudecker BA, Formby B. Lactate stimulates fibroblast expression of hyaluronan and CD44: the Warburg effect revisited. Exp Cell Res. 2002;276(1):24–31.PubMedCrossRef
51.
Ding J, Karp JE, Emadi A. Elevated lactate dehydrogenase (LDH) can be a marker of immune suppression in cancer: Interplay between hematologic and solid neoplastic clones and their microenvironments. Cancer Biomark. 2017;19(4):353–63.PubMedCrossRef
52.
Zhao J, Huang X, Xu Z, Dai J, He H, Zhu Y, et al. LDHA promotes tumor metastasis by facilitating epithelial-mesenchymal transition in renal cell carcinoma. Mol Med Rep. 2017;16(6):8335–44.PubMedCrossRef
53.
Liu M, Quek LE, Sultani G, Turner N. Epithelial-mesenchymal transition induction is associated with augmented glucose uptake and lactate production in pancreatic ductal adenocarcinoma. Cancer Metab. 2016;4:19.PubMedPubMedCentralCrossRef
54.
Ghafouri-Fard S, Khoshbakht T, Hussen BM, Taheri M, Samsami M. Emerging role of circular RNAs in the pathogenesis of ovarian cancer. Cancer Cell Int. 2022;22(1):172.PubMedPubMedCentralCrossRef
55.
Kristensen LS, Jakobsen T, Hager H, Kjems J. The emerging roles of circRNAs in cancer and oncology. Nat Rev Clin Oncol. 2022;19(3):188–206.PubMedCrossRef
56.
Hsu MT, Coca-Prados M. Electron microscopic evidence for the circular form of RNA in the cytoplasm of eukaryotic cells. Nature. 1979;280(5720):339–40.ADSPubMedCrossRef
57.
58.
Ashwal-Fluss R, Meyer M, Pamudurti NR, Ivanov A, Bartok O, Hanan M, et al. circRNA biogenesis competes with pre-mRNA splicing. Mol Cell. 2014;56(1):55–66.PubMedCrossRef
59.
Enuka Y, Lauriola M, Feldman ME, Sas-Chen A, Ulitsky I, Yarden Y. Circular RNAs are long-lived and display only minimal early alterations in response to a growth factor. Nucleic Acids Res. 2016;44(3):1370–83.PubMedCrossRef
60.
Rybak-Wolf A, Stottmeister C, Glažar P, Jens M, Pino N, Giusti S, et al. Circular RNAs in the mammalian brain are highly abundant, conserved, and dynamically expressed. Mol Cell. 2015;58(5):870–85.PubMedCrossRef
61.
62.
63.
64.
Chen LL. The expanding regulatory mechanisms and cellular functions of circular RNAs. Nat Rev Mol Cell Biol. 2020;21(8):475–90.PubMedCrossRef
65.
66.
Cocquerelle C, Mascrez B, Hétuin D, Bailleul B. Mis-splicing yields circular RNA molecules. Faseb j. 1993;7(1):155–60.PubMedCrossRef
67.
Capel B, Swain A, Nicolis S, Hacker A, Walter M, Koopman P, et al. Circular transcripts of the testis-determining gene Sry in adult mouse testis. Cell. 1993;73(5):1019–30.PubMedCrossRef
68.
Li RC, Ke S, Meng FK, Lu J, Zou XJ, He ZG, et al. CiRS-7 promotes growth and metastasis of esophageal squamous cell carcinoma via regulation of miR-7/HOXB13. Cell Death Dis. 2018;9(8):838.PubMedPubMedCentralCrossRef
69.
Zeng K, Chen X, Xu M, Liu X, Hu X, Xu T, et al. CircHIPK3 promotes colorectal cancer growth and metastasis by sponging miR-7. Cell Death Dis. 2018;9(4):417.PubMedPubMedCentralCrossRef
70.
Luan W, Shi Y, Zhou Z, Xia Y, Wang J. circRNA_0084043 promote malignant melanoma progression via miR-153-3p/Snail axis. Biochem Biophys Res Commun. 2018;502(1):22–9.PubMedCrossRef
71.
Yu CY, Li TC, Wu YY, Yeh CH, Chiang W, Chuang CY, et al. The circular RNA circBIRC6 participates in the molecular circuitry controlling human pluripotency. Nat Commun. 2017;8(1):1149.ADSPubMedPubMedCentralCrossRef
72.
Sheng R, Li X, Wang Z, Wang X. Circular RNAs and their emerging roles as diagnostic and prognostic biomarkers in ovarian cancer. Cancer Lett. 2020;473:139–47.PubMedCrossRef
73.
Foruzandeh Z, Zeinali-Sehrig F, Nejati K, Rahmanpour D, Pashazadeh F, Seif F, et al. CircRNAs as potent biomarkers in ovarian cancer: a systematic scoping review. Cell Mol Biol Lett. 2021;26(1):41.PubMedPubMedCentralCrossRef
74.
Liu F, Wu X, Zhu H, Wang F. Dysregulated expression of circular RNAs serve as diagnostic and prognostic markers in ovarian and cervical cancer: a PRISMA-compliant systematic review and meta-analysis. Medicine (Baltimore). 2021;100(39): e27352.PubMedCrossRef
75.
76.
Chen Y, Ye X, Xia X, Lin X. Circular RNA ABCB10 correlates with advanced clinicopathological features and unfavorable survival, and promotes cell proliferation while reduces cell apoptosis in epithelial ovarian cancer. Cancer Biomark. 2019;26(2):151–61.PubMedCrossRef
77.
Liu N, Zhang J, Zhang LY, Wang L. CircHIPK3 is upregulated and predicts a poor prognosis in epithelial ovarian cancer. Eur Rev Med Pharmacol Sci. 2018;22(12):3713–8.PubMed
78.
Ning L, Long B, Zhang W, Yu M, Wang S, Cao D, et al. Circular RNA profiling reveals circEXOC6B and circN4BP2L2 as novel prognostic biomarkers in epithelial ovarian cancer. Int J Oncol. 2018;53(6):2637–46.PubMed
79.
Wang W, Wang J, Zhang X, Liu G. Serum circSETDB1 is a promising biomarker for predicting response to platinum-taxane-combined chemotherapy and relapse in high-grade serous ovarian cancer. Onco Targets Ther. 2019;12:7451–7.PubMedPubMedCentralCrossRef
80.
81.
Qiu Y, Chen Y, Agbede O, Eshaghi E, Peng C. Circular RNAs in epithelial ovarian cancer: from biomarkers to therapeutic targets. Cancers (Basel). 2022;14(22):5711.PubMedCrossRef
82.
Chen S, Wu W, Li QH, Xie BM, Shen F, Du YP, et al. Circ-NOLC1 promotes epithelial ovarian cancer tumorigenesis and progression by binding ESRP1 and modulating CDK1 and RhoA expression. Cell Death Discov. 2021;7(1):22.PubMedPubMedCentralCrossRef
83.
Xia B, Zhao Z, Wu Y, Wang Y, Zhao Y, Wang J. Circular RNA circTNPO3 regulates paclitaxel resistance of ovarian cancer cells by miR-1299/NEK2 signaling pathway. Mol Ther Nucleic Acids. 2020;21:780–91.PubMedPubMedCentralCrossRef
84.
Yang C, Yuan W, Yang X, Li P, Wang J, Han J, et al. Circular RNA circ-ITCH inhibits bladder cancer progression by sponging miR-17/miR-224 and regulating p21, PTEN expression. Mol Cancer. 2018;17(1):19.PubMedPubMedCentralCrossRef
85.
Guo W, Zhang J, Zhang D, Cao S, Li G, Zhang S, et al. Polymorphisms and expression pattern of circular RNA circ-ITCH contributes to the carcinogenesis of hepatocellular carcinoma. Oncotarget. 2017;8(29):48169–77.PubMedPubMedCentralCrossRef
86.
Lin C, Xu X, Yang Q, Liang L, Qiao S. Circular RNA ITCH suppresses proliferation, invasion, and glycolysis of ovarian cancer cells by up-regulating CDH1 via sponging miR-106a. Cancer Cell Int. 2020;20:336.PubMedPubMedCentralCrossRef
87.
Chen L, Zhang F, Sheng XG, Zhang SQ, Chen YT, Liu BW. MicroRNA-106a regulates phosphatase and tensin homologue expression and promotes the proliferation and invasion of ovarian cancer cells. Oncol Rep. 2016;36(4):2135–41.PubMedCrossRef
88.
Lai Y, Zhou B, Tan Q, Xu J, Wan T, Zhang L. LINC00116 enhances cervical cancer tumorigenesis through miR-106a/c-Jun pathway. J Cell Biochem. 2020;121(3):2247–57.PubMedCrossRef
89.
Zhao J, Klausen C, Qiu X, Cheng JC, Chang HM, Leung PC. Betacellulin induces Slug-mediated down-regulation of E-cadherin and cell migration in ovarian cancer cells. Oncotarget. 2016;7(20):28881–90.PubMedPubMedCentralCrossRef
90.
Luo L, Gao YQ, Sun XF. Circular RNA ITCH suppresses proliferation and promotes apoptosis in human epithelial ovarian cancer cells by sponging miR-10a-α. Eur Rev Med Pharmacol Sci. 2018;22(23):8119–26.PubMed
91.
Ye J, Wu D, Shen J, Wu P, Ni C, Chen J, et al. Enrichment of colorectal cancer stem cells through epithelial-mesenchymal transition via CDH1 knockdown. Mol Med Rep. 2012;6(3):507–12.PubMed
92.
Bolaños JP, Almeida A, Moncada S. Glycolysis: a bioenergetic or a survival pathway? Trends Biochem Sci. 2010;35(3):145–9.PubMedCrossRef
93.
Qu D, Zou X, Liu Z. Propofol modulates glycolysis reprogramming of ovarian tumor via restraining circular RNA-zinc finger RNA-binding protein/microRNA-212-5p/superoxide dismutase 2 axis. Bioengineered. 2022;13(5):11881–92.PubMedPubMedCentralCrossRef
94.
Liu H, Dilger JP, Lin J. Effects of local anesthetics on cancer cells. Pharmacol Ther. 2020;212: 107558.PubMedCrossRef
95.
Ren YL, Zhang W. Propofol promotes apoptosis of colorectal cancer cells via alleviating the suppression of lncRNA HOXA11-AS on miRNA let-7i. Biochem Cell Biol. 2020;98(2):90–8.PubMedCrossRef
96.
Yu X, Gao Y, Zhang F. Propofol inhibits pancreatic cancer proliferation and metastasis by up-regulating miR-328 and down-regulating ADAM8. Basic Clin Pharmacol Toxicol. 2019;125(3):271–8.PubMedCrossRef
97.
Sui H, Zhu C, Li Z, Yang J. Propofol suppresses gastric cancer tumorigenesis by modulating the circular RNA-PVT1/miR-195-5p/E26 oncogene homolog 1 axis. Oncol Rep. 2020;44(4):1736–46.PubMed
98.
Wang P, Chen J, Mu LH, Du QH, Niu XH, Zhang MY. Propofol inhibits invasion and enhances paclitaxel- induced apoptosis in ovarian cancer cells through the suppression of the transcription factor slug. Eur Rev Med Pharmacol Sci. 2013;17(13):1722–9.PubMed
99.
Olson SH, Carlson MD, Ostrer H, Harlap S, Stone A, Winters M, et al. Genetic variants in SOD2, MPO, and NQO1, and risk of ovarian cancer. Gynecol Oncol. 2004;93(3):615–20.PubMedCrossRef
100.
Bayer JL, Spitz DR, Christensen D, McCormick ML, Farley D, DeGeest K, et al. Biobehavioral and neuroendocrine correlates of antioxidant enzyme activity in ovarian carcinoma. Brain Behav Immun. 2015;50:58–62.PubMedPubMedCentralCrossRef
101.
Yang H, Guo Y, Zhang Y, Wang D, Zhang G, Hou J, et al. Circ_MUC16 attenuates the effects of Propofol to promote the aggressive behaviors of ovarian cancer by mediating the miR-1182/S100B signaling pathway. BMC Anesthesiol. 2021;21(1):297.PubMedPubMedCentralCrossRef
102.
Yang T, Cheng J, Yang Y, Qi W, Zhao Y, Long H, et al. S100B Mediates Stemness of Ovarian Cancer Stem-Like Cells Through Inhibiting p53. Stem Cells. 2017;35(2):325–36.PubMedCrossRef
103.
Yang T, Cheng J, You J, Yan B, Liu H, Li F. S100B promotes chemoresistance in ovarian cancer stem cells by regulating p53. Oncol Rep. 2018;40(3):1574–82.PubMed
104.
Hou W, Zhang Y. Circ_0025033 promotes the progression of ovarian cancer by activating the expression of LSM4 via targeting miR-184. Pathol Res Pract. 2021;217: 153275.PubMedCrossRef
105.
Wu S, Le H. Dual roles of PKM2 in cancer metabolism. Acta Biochim Biophys Sin (Shanghai). 2013;45(1):27–35.PubMedCrossRef
106.
Pan Y, Xu T, Liu Y, Li W, Zhang W. Upregulated circular RNA circ_0025033 promotes papillary thyroid cancer cell proliferation and invasion via sponging miR-1231 and miR-1304. Biochem Biophys Res Commun. 2019;510(2):334–8.PubMedCrossRef
107.
Ye M, Hou H, Shen M, Dong S, Zhang T. Circular RNA circFOXM1 Plays a Role in Papillary Thyroid Carcinoma by Sponging miR-1179 and Regulating HMGB1 Expression. Mol Ther Nucleic Acids. 2020;19:741–50.PubMedCrossRef
108.
Xue R, Hua L, Xu W, Gao Y, Pang Y, Hao J. Derivation and validation of the potential core genes in pancreatic cancer for tumor-stroma crosstalk. Biomed Res Int. 2018;2018:4283673.PubMedPubMedCentralCrossRef
109.
Wang J, Wu A, Yang B, Zhu X, Teng Y, Ai Z. Profiling and bioinformatics analyses reveal differential circular RNA expression in ovarian cancer. Gene. 2020;724: 144150.PubMedCrossRef
110.
Liu Y, He X, Chen Y, Cao D. Long non-coding RNA LINC00504 regulates the Warburg effect in ovarian cancer through inhibition of miR-1244. Mol Cell Biochem. 2020;464(1–2):39–50.PubMedCrossRef
111.
Xie, W., L.U. Liu, C. He, M. Zhao, R. Ni, Z. Zhang, et al., Circ_0002711 knockdown suppresses cell growth and aerobic glycolysis by modulating miR-1244/ROCK1 axis in ovarian cancer. J Biosci, 2021. 46.
112.
113.
Ma X, Dang Y, Shao X, Chen X, Wu F, Li Y. Ubiquitination and long non-coding RNAs regulate actin cytoskeleton regulators in cancer progression. Int J Mol Sci. 2019;20(12):2997.PubMedPubMedCentralCrossRef
114.
Reymond N, Im JH, Garg R, Cox S, Soyer M, Riou P, et al. RhoC and ROCKs regulate cancer cell interactions with endothelial cells. Mol Oncol. 2015;9(6):1043–55.PubMedPubMedCentralCrossRef
115.
Zhang X, Zhang L, Du Y, Zheng H, Zhang P, Sun Y, et al. A novel FOXM1 isoform, FOXM1D, promotes epithelial-mesenchymal transition and metastasis through ROCKs activation in colorectal cancer. Oncogene. 2017;36(6):807–19.PubMedCrossRef
116.
Farooqi AA, Zahid R, Naureen H, Attar R, Gazouli M, Berardi R, et al. Regulation of ROCK1/2 by long non-coding RNAs and circular RNAs in different cancer types. Oncol Lett. 2022;23(5):159.PubMedPubMedCentralCrossRef
117.
Vennin C, Rath N, Pajic M, Olson MF, Timpson P. Targeting ROCK activity to disrupt and prime pancreatic cancer for chemotherapy. Small GTPases. 2020;11(1):45–52.PubMedCrossRef
118.
Fu Y, Sun H. The molecular mechanism of circRHOBTB3 inhibits the proliferation and invasion of epithelial ovarian cancer by serving as the ceRNA of miR-23a-3p. J Ovarian Res. 2022;15(1):66.PubMedPubMedCentralCrossRef
119.
Yalan, S., L. Yanfang, C. He, and T. Yujie, Circular RNA circRHOBTB3 inhibits ovarian cancer progression through PI3K/AKT signaling pathway. Panminerva Med, 2020.
120.
121.
Chen Y, Li C, Tan C, Liu X. Circular RNAs: a new frontier in the study of human diseases. J Med Genet. 2016;53(6):359–65.PubMedCrossRef
122.
Dahl M, Daugaard I, Andersen MS, Hansen TB, Grønbæk K, Kjems J, et al. Enzyme-free digital counting of endogenous circular RNA molecules in B-cell malignancies. Lab Invest. 2018;98(12):1657–69.PubMedPubMedCentralCrossRef
123.
Kristensen LS. Profiling of circRNAs using an enzyme-free digital counting method. Methods. 2021;196:11–6.PubMedCrossRef
124.
Du WW, Yang W, Li X, Awan FM, Yang Z, Fang L, et al. A circular RNA circ-DNMT1 enhances breast cancer progression by activating autophagy. Oncogene. 2018;37(44):5829–42.PubMedCrossRef
125.
Lu M, Wu Y, Zeng B, Sun J, Li Y, Luo J, et al. CircEHMT1 inhibits metastatic potential of breast cancer cells by modulating miR-1233-3p/KLF4/MMP2 axis. Biochem Biophys Res Commun. 2020;526(2):306–13.PubMedCrossRef
Metadata
Title
CircRNA-regulated glucose metabolism in ovarian cancer: an emerging landscape for therapeutic intervention
Authors
Yaolong Wang
Xi Chen
Yongxiu Yang
Publication date
14-08-2023
Publisher
Springer International Publishing
Published in
Clinical and Translational Oncology / Issue 3/2024
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-023-03285-4

Other articles of this Issue 3/2024

Clinical and Translational Oncology 3/2024 Go to the issue

RESEARCH ARTICLE

Case–control study assessing the impact of COVID19 in advanced kidney cancer patients treated with antiangiogenics or immunotherapy: the COVID-REN study

RESEARCH ARTICLE

The impact of boost radiation therapy after hysterectomy on cervical cancer patients with close or positive resection margins

RESEARCH ARTICLE

Impact of bone metastasis on the prognosis of non-small cell lung cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis

RESEARCH ARTICLE

Clinical significance of CD166 and HER-2 in different types of gastric cancer

RESEARCH ARTICLE

Outcomes with atezolizumab in metastatic urothelial cancer: real-world data from a single institution

REVIEW ARTICLE

Difficulties on the access to innovative targeted therapies for lung cancer in Spain
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits